Pharmaceuticals (Basel, Switzerland)
December 28, 2022
Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al.
13 citations
Psychedelic compounds found in Psilocybe mushrooms are being studied for treating central nervous system disorders, but obtaining enough pure material from fungi for research is challenging. This review examines synthetic chemistry methods to produce these molecules, covering classic historical syntheses, modern metal-catalyzed coupling reactions, and biocatalytic approaches. The authors note that alternative synthetic routes will likely be needed as therapeutic interest in these compounds grows.
Qeios
December 9, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
Alcohol use disorder involves excessive drinking, and existing medications often fail to prevent relapse. Psilocybin is being studied as a treatment for substance use disorders. This review of recent clinical trials finds that psilocybin appears to reduce craving for alcohol, but its effect on overall alcohol consumption is less clear. The authors note that future trials would benefit from larger sample sizes and standardized tests.
Preprints.org
October 17, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
preprint
Alcohol use disorder involves excessive drinking, and current medications often do not prevent relapse. Psilocybin is being studied for treating substance use disorders. This review of recent clinical trials finds that psilocybin appears to reduce craving, but its effect on overall alcohol consumption is less clear. Future trials would benefit from larger sample sizes and standardized tests.
Journal of clinical psychopharmacology
Ewen Kervadec, Aurore Bezo, Raphaël Serreau et al.
Ibogaine, a psychedelic compound distinct from psilocybin or LSD, has attracted interest for treating substance use and psychiatric disorders, but clinical evidence remains weak. A narrative review of studies from 1990 to 2025 found 24 studies and 38 case reports. Most positive efficacy data come from uncontrolled, open-label, or retrospective studies with high risk of bias. No double-blind randomized controlled trial has shown ibogaine or its metabolite noribogaine to effectively treat opioid use disorder. One small trial reported significant effects for cocaine use disorder. Observational data suggest possible symptom relief for opioid use disorder, PTSD, or polysubstance dependence, but findings are exploratory. Serious adverse events, especially cardiotoxicity from QT prolongation, pose considerable risk given unproven efficacy. Current evidence is insufficient to support clinical use.